Another patient was scheduled for treatment with docetaxel-pertuzumab-trastuzumab for a presumed metastatic HER2-amplified adenocarcinoma in the head and neck region, after a potential HER2-overexpression on immunohistochemistry. This evidence concerns the gene ERBB2 and adenocarcinoma.